Argenx (ARGX) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, approved Vyvdura for adults with chronic inflammatory demyelinating polyneuropathy. Vyvdura is approved for CIDP as a once weekly 30-to-90 second subcutaneous injection, which can be self-administered at home, and is the first and only neonatal Fc receptor blocker approved for the treatment of CIDP.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $723 from $639 at Wells Fargo
- Argenx price target raised to EUR 740 from EUR 620 at JPMorgan
- Argenx price target raised to EUR 670 from EUR 650 at Barclays
- Argenx price target raised to $706 from $675 at Evercore ISI
- Argenx price target raised to $675 from $646 at Oppenheimer